Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

1 Nov 2021 17:33

RNS Number : 9809Q
Silence Therapeutics PLC
01 November 2021
 

 

 

Results of General Meeting

1 November 2021

 

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that at its general meeting held today, 1 November 2021, all resolutions set out in the notice of meeting were duly passed on a poll.

 

The votes were as follows:

 

Special Resolution

Votes for

%

Votes against

%

Votes total

% of ISC voted

Votes withheld

1 - Approve the cancellation of the admission to trading on AIM of the ordinary shares of nominal value £0.05 each in the capital of the Company and authorise the directors of the Company to take all action reasonable or necessary to effect such cancellation

31,092,066

 

99.47

 

 

166,904

 

 

0.53

 

 

31,258,970

 

 

34.82

 

 

4,408,363

 

 

2 - Approve, conditional on the passing of Resolution 1, the amendment to the articles of association of the Company

31,354,885

99.89

34,007

0.11

31,388,892

35.00

4,278,441

 

The number of the Company's ordinary shares in issue as at the date of the meeting was 89,784,720 ordinary shares of nominal value £0.05 each.

 

A vote withheld is not a vote in law and has not been counted in the total votes or the calculation of the proportion of votes for and against the resolutions.

 

The Company confirms that, as at today's date, the timetable for the cancellation of the admission to trading on AIM of the Company's ordinary shares is as follows:

 

Last date for receipt by Link Group from certificated shareholders of duly completed block transfer participation request forms and original share certificates

3 November 2021 at 1.00 p.m.

Last date for receipt by The Bank of New York Mellon from CREST holders of duly completed issuance forms

17 November 2021 at 3.00 p.m.

Expected date of issuance of ADSs to block transfer participants

24 November 2021

Expected date of posting of ADS confirmations to shareholders by The Bank of New York Mellon

24 November 2021

Last day of dealings in the Ordinary Shares on AIM

29 November 2021

Cancellation of admission to trading on AIM of the Ordinary Shares

30 November 2021 at 7.00 a.m.

 

 

 

Enquiries:

 

Silence Therapeutics plc

 Gem Hopkins, Head of IR & Corporate Communications

Tel: +1 (646) 637-3208

 

Investec Bank plc (Nominated Adviser and Broker)

Daniel Adams/Gary Clarence

 

 

Tel: +44 (0) 20 7597 5970

European PR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

silencetherapeutics@consilium-comms.com

 

Tel: +44 (0) 20 3709 5700

 

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMDFLFBFFLLFBK
Date   Source Headline
11th Jul 20187:00 amRNSLicensee Quark Pharmaceuticals Patient Dosed Ph 3
21st Jun 20187:00 amRNSSilence Strengthens Board and Leadership Team
18th Jun 20184:35 pmRNSPrice Monitoring Extension
15th Jun 20187:00 amRNSPresents Data on Lead Programme SLN124 at EHA
4th Jun 201810:15 amRNSSilence Therapeutics Announces Leadership Change
24th Apr 20187:00 amRNSResults of AGM
19th Apr 20185:00 pmRNSAdditional Listing
3rd Apr 20187:00 amRNSLitigation Update (Portugal and US)
26th Mar 20187:00 amRNSSilence to Present at Scientific Conferences
7th Mar 20187:00 amRNSNotice of AGM
6th Mar 20187:00 amRNSPreliminary results year ended 31 December 2017
5th Mar 20187:00 amRNSSilence to present at Cowen Health Care Conference
22nd Feb 20183:40 pmRNSHolding(s) in Company
20th Feb 20187:00 amRNSNotice of Results
15th Feb 20182:27 pmRNSAdditional Listing
2nd Feb 201811:38 amRNSGrant of share options and restricted stock units
2nd Feb 20188:58 amRNSHolding(s) in Company
31st Jan 201811:48 amRNSHolding(s) in Company
22nd Jan 20187:00 amRNSKey European patent granted
8th Jan 20187:00 amRNSPost year end business update
28th Dec 20177:00 amRNSFurther Partial Disposal - Arrowhead common shares
15th Dec 20174:40 pmRNSSecond Price Monitoring Extn
15th Dec 20174:35 pmRNSPrice Monitoring Extension
14th Dec 20174:35 pmRNSPrice Monitoring Extension
11th Dec 20177:00 amRNSFurther Partial Disposal - Arrowhead common shares
4th Dec 20177:00 amRNSPartial Disposal of Arrowhead common shares
20th Nov 20177:00 amRNSUpdate on litigation matters
14th Nov 20177:00 amRNSCapital Markets Day
3rd Nov 20177:00 amRNSUpdate on Litigation Matters
2nd Nov 20174:40 pmRNSSecond Price Monitoring Extn
2nd Nov 20174:35 pmRNSPrice Monitoring Extension
26th Oct 20179:24 amRNSHolding(s) in Company
24th Oct 20173:59 pmRNSHolding(s) in Company
19th Oct 20175:50 pmRNSHolding(s) in Company
18th Oct 20172:31 pmRNSHolding(s) in Company
18th Oct 20177:00 amRNSFurther US patents granted
17th Oct 20173:08 pmRNSServing of claim in the UK High Court
16th Oct 20177:00 amRNSAppointment of Non-Executive Chair
11th Oct 20177:00 amRNSKey US patent granted
6th Oct 20172:40 pmRNSHolding(s) in Company
28th Sep 20171:10 pmRNSHolding(s) in Company
27th Sep 20172:39 pmRNSHolding(s) in Company
27th Sep 20179:48 amRNSHolding(s) in Company
26th Sep 201711:48 amRNSHolding(s) in Company
22nd Sep 20174:00 pmRNSHolding in Company
22nd Sep 20173:15 pmRNSHolding in Company
22nd Sep 20172:15 pmRNSHolding in Company
22nd Sep 20172:01 pmRNSHolding in Company
22nd Sep 20172:00 pmRNSHolding in Company
20th Sep 201712:07 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.